Seres Therapeutics, Inc. (MCRB) AI Stock Analysis

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing bacterial consortia to interact functionally with host cells and tissues to combat disease. Its lead candidate, SER-109, is an oral therapeutic that completed Phase III clinical trials for clostridium difficile infection (CDI). The pipeline also includes SER-155 in Phase Ib trials targeting infections and graft versus host disease in transplant patients, alongside SER-287 and SER-301 in Phase Ib trials for ulcerative colitis. Additionally, the company is developing SER-401 for metastatic melanoma and SER-262 for CDI. Headquartered in Cambridge, Massachusetts, Seres maintains collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center.

Revenue has shown sharp volatility over recent years, moving from $144.9M in FY2021 down to $7.1M in FY2022, rising to $126.3M in FY2023, and falling 99.4% to $789,000 in FY2025. Over the 5-year period from FY2019 to FY2025, revenue contracted at a CAGR of -53.0%. In FY2025, gross margin was -423.8% and operating margin was -11910.1%, while net income was positive at $5.7M. For the latest quarter ended June 30, 2026, quarterly revenue fell 93.4% year-over-year, and trailing twelve-month revenue was $1.9M with an operating margin of -2101.4% and an EPS of -$2.42.

As of June 30, 2026, Seres Therapeutics held $15.6M in cash and short-term investments and total debt of $56.6M, resulting in net debt of $41.0M. Total assets stood at $101.6M and shareholders' equity was $34.5M, yielding a debt-to-equity ratio of 1.64 and a current ratio of 2.11. For FY2025, operating cash flow was $1.1M and free cash flow was $865,000 after capital expenditures of $252,000. Over the past five years, the company's share count increased 109.9%.

MCRB trades at an enterprise value of $81.4M and a price-to-sales multiple of 13.1x, compared to 4.1x for the median of its US-listed Healthcare peers. Its EV-to-EBITDA stands at 3.3x versus the peer median of 12.0x, while its forward P/E is 10.3x compared to 17.3x for the peer group. Over the past year, the stock fell 87.2%, underperforming the SPY return of 16.8%. Over five years, the stock declined 98.1% compared to an 83.0% gain for the SPY.

Wall Street coverage includes 2 Strong Buy ratings and no Buy, Hold, or Sell ratings. The mean price target is $17.00, representing an upside of 591.1% over the last close of $2.46. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $13.8M and an EPS of -$3.52. For the following fiscal year, 2 analysts expect revenue of $273,500 and an EPS of -$4.95. Over the last four quarters, the company beat EPS estimates 2 times. The next earnings date is November 4, 2026.

This page is an AI-written research summary of Seres Therapeutics, Inc. (MCRB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MCRB income statement, MCRB balance sheet, MCRB key metrics, MCRB analyst forecast, MCRB chart. See the MCRB stock overview for the latest quote and news.